ByTrending Posts
How Roche’s $55 Million Bet on Manifold Bio’s…
Key Highlights• Roche deepens its AI-first drug discovery strategy with a foundational partnership targeting blood-brain barrier (BBB) breakthroughs•…
Will Lilly’s AI Supercomputer with NVIDIA Become the…
• Lilly partners with NVIDIA to build what it calls the most powerful AI supercomputer operated by a…
Could Merck’s USD 349M Collaboration with Variational AI…
Key Highlights A Strategic Alliance Targeting Hard-to-Crack Therapeutic SpaceVariational AI announced a major collaboration with Merck to deploy…
Could Excelsior Sciences’ $95M AI Surge Redefine How…
Key Highlights • $95M funding round positions Excelsior to compress multi-month chemistry cycles into weeks, reshaping competitive timelines…
Will Novartis’s $12 Billion Avidity Deal Ignite a…
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) — the company’s largest…
Can Eli Lilly and NVIDIA’s AI Supercomputer Redefine…
Key Insights:• Lilly builds one of pharma’s first NVIDIA-powered DGX SuperPODs, training AI on millions of experiments to…
Could the Algen Biotechnologies – AstraZeneca $555 Million…
Key Highlights / Executive Take-aways: Strategic Significance of the PartnershipThe alliance between Algen Biotechnologies and AstraZeneca marks a…
Can Takeda and Nabla Bio’s $1 Billion AI…
Key Highlights: AI Takes Center Stage in Takeda’s R&D RebootAfter narrowing its research focus to small molecules, biologics,…
Could Cohere’s New Paris Office Accelerate AI Adoption…
Key Insights: Expanding Footprint in Europe Cohere, a Canadian AI firm known for developing large language models and…
Trending Posts
Latest Stories
Can Localized Manufacturing Shield Big Pharma from Trade Volatility? Novartis Targets Zero U.S. Tariff Exposure by Mid-2026
23 January 2026 Executive Summary Novartis CEO Vas Narasimhan has outlined a decisive trade-risk mitigation…
Is U.S. Manufacturing the Next Growth Hedge for Big Pharma? Novartis Commits $23 Billion to Domestic Expansion
23 January 2026 Executive Summary Novartis has unveiled a $23 billion investment plan to significantly…
Can Ianalumab Anchor Novartis’ Next Growth Cycle as Patent Pressures Mount?
23 Jan 2026 Executive Summary Novartis has secured Breakthrough Therapy designation for ianalumab, a late-stage…
Can AI Become the Backbone of Global Health Equity? Gates Foundation and OpenAI Launch $50 Million Horizon1000 Initiative in Africa
Executive Summary The Bill & Melinda Gates Foundation and OpenAI have announced a $50 million…
Gallery
